News 
Market Data 
Discover
midastouch017
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
| Ticker | Board | News | Price | Change | Chg% | Added | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc | 5.02 | -0.15 | -2.90% | 11/03/2022 | |||||
|
My AUPH Pitch: L
|
||||||||||
| BLRX | BioLineRx Ltd | 0.6522 | -0.0329 | -4.80% | 03/18/2022 | |||||
| BCLI | BrainStorm Cell Therapeutics Inc | 0.48 | 0.013 | 2.78% | 01/03/2022 | |||||
| BWAY | BrainsWay | 5.33 | -0.12 | -2.20% | 12/12/2022 | |||||
| CANF | Can Fite BioPharma Ltd | 2.09 | -0.0518 | -2.42% | 11/11/2013 | |||||
| CGEN | Compugen Ltd | 2.01 | -0.08 | -3.83% | 12/21/2023 | |||||
| GMDAQ | Gamida Cell Ltd | 0.0137 | 0.0 | 0.00% | 05/12/2020 | |||||
|
My GMDAQ Pitch: Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies
Business Wire•May 12, 2020 — Study met primary endpoint of time to neutrophil engraftment — — Omidubicel represents potential transformative treatment o |
||||||||||
| KMDA | Kamada | 5.535 | -0.025 | -0.45% | 03/18/2022 | |||||
| MDWD | Mediwound Ltd | 18.3 | 0.59 | 3.33% | 09/28/2021 | |||||
| ORMP | Oramed Pharmaceuticals Inc | 2.395 | 0.015 | 0.63% | 06/01/2023 | |||||
| PSTI | Pluristem Therapeutics Inc | 03/18/2022 | ||||||||
| PLX | PROTALIX BIOTHERAPEUTICS, INC. | 1.1 | -0.15 | -12.00% | 08/11/2020 | |||||
|
My PLX Pitch: Huge potential:
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human a–Galactosidase–A prot |
||||||||||
| RDHL | RedHill Biopharma Ltd | 0.4606 | 0.0026 | 0.57% | 08/11/2020 | |||||
|
My RDHL Pitch: Huge potential:
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults3, Talicia® for the treatment of Helicobacter pylori (H. pyl |
||||||||||
